Welcome to our dedicated page for Lantheus Holding news (Ticker: LNTH), a resource for investors and traders seeking the latest updates and insights on Lantheus Holding stock.
Lantheus Holdings, Inc. (NASDAQ: LNTH) is a leading radiopharmaceutical-focused company, dedicated to the development, manufacture, and commercialization of innovative diagnostic imaging agents and products. Headquartered in North Billerica, Massachusetts, and with additional offices in Puerto Rico and Canada, Lantheus has been a pivotal player in the medical imaging industry for over 65 years.
The company's primary subsidiary, Lantheus Medical Imaging, Inc. (LMI), specializes in diagnostic imaging solutions primarily for cardiovascular diseases. Key products include the echocardiography contrast agent DEFINITY® Vial, the technetium-based generator TechneLite®, and the inhaled radiopharmaceutical imaging agent Xenon Xe 133 Gas for lung imaging.
Lantheus is organized into three main business units: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostics focuses on products that assist healthcare professionals in detecting and monitoring diseases, particularly in cardiology. Radiopharmaceutical Oncology offers diagnostics and therapeutic solutions that help healthcare providers manage cancer. Through its Strategic Partnerships, Lantheus collaborates to advance precision medicine using biomarkers and digital solutions.
Recent achievements include strategic transactions to enhance their pipeline for neuroendocrine tumors and prostate cancer. Lantheus has partnered with Perspective Therapeutics, which has developed a best-in-class alpha therapy platform, enabling Lantheus to expand its pipeline into promising alpha therapies.
Financially, Lantheus has shown robust performance. The company reported record revenues of $1.3 billion for the full year 2023, marking a 38.6% increase from 2022. This growth was driven by the successful commercialization of innovative products and strategic acquisitions.
In the Radiopharmaceutical Oncology space, the company’s Abbreviated New Drug Application (ANDA) for Lutetium Lu 177 Dotatate has been accepted by the FDA. This product is intended for treating somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Lantheus continues to drive innovation and growth through its robust pipeline and strategic collaborations. Recent leadership changes have positioned the company for its next phase of growth, with Brian Markison taking over as CEO from March 2024, following the successful tenure of Mary Anne Heino.
For ongoing updates and more information, visit their website at www.lantheus.com.
Lantheus Holdings (NASDAQ: LNTH), a leading radiopharmaceutical company, has announced its participation in three major upcoming investor conferences in February and March 2025. The company's management team will present at:
- B. Riley Securities Precision Oncology & Radiopharma Day in New York (February 28)
- TD Cowen 45th Annual Health Care Conference in Boston (March 4, 2:30 PM ET)
- Leerink Global Healthcare Conference 2025 in Miami (March 11, 1:40 PM ET)
Live webcasts will be available for the TD Cowen and Leerink conferences through the Investors section of Lantheus's website. Replay access will be maintained for at least 30 days following the presentations.
Lantheus Holdings (NASDAQ: LNTH) has announced it will host a conference call and webcast to discuss its Q4 and full year 2024 financial results on Wednesday, February 26, 2025, at 8:00 a.m. ET.
Participants are encouraged to register fifteen minutes before the scheduled start time through the company's investor relations website to avoid delays. A replay of the webcast will be available approximately two hours after the event and will remain accessible for at least 30 days on the same web page.
Lantheus Holdings (NASDAQ: LNTH) has announced upcoming presentations of piflufolastat F 18 (PYLARIFY) data at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco. Two key presentations will showcase PYLARIFY's capabilities: one focusing on early detection of recurrent prostate cancer in patients with minimal PSA levels, and another examining PYLARIFY's role in newly-diagnosed and recurrent prostate cancer patients based on registry data.
The presentations are scheduled for February 13, 2025, during Poster Session A, with studies from the University of California's Department of Radiation Oncology and Carolina Urologic Research Center. The research highlights PYLARIFY's effectiveness in real-world applications and its ability to detect prostate cancer recurrence in low PSA cases.
Lantheus Holdings (NASDAQ: LNTH) has appointed Dr. Phuong Khanh (P.K.) Morrow to its Board of Directors, effective February 1, 2025. Dr. Morrow, currently Head of the Oncology Therapeutic Area Unit at Takeda, brings extensive expertise in clinical development and oncology therapeutics. She will serve as a member of the Board's Science and Technology Committee.
This appointment marks the second new board addition in five months, bringing the total number of directors to eleven, with nine being independent. Dr. Morrow's previous roles include Chief Medical Officer at CRISPR Therapeutics and Vice President at Amgen, where she led global therapeutic areas in oncology and related fields. She holds an M.D. from the University of Texas Medical School at Houston and completed specialized training at prestigious institutions.
Lantheus Holdings (NASDAQ: LNTH) has announced a definitive agreement to acquire Evergreen Theragnostics for an upfront payment of $250 million, with potential additional milestone payments of up to $752.5 million. The acquisition aims to transform Lantheus into a fully integrated radiopharmaceutical company.
The deal brings significant strategic advantages, including enhanced manufacturing infrastructure, a revenue-generating CDMO business, and the addition of OCTEVY™, a registrational-stage diagnostic agent for neuroendocrine tumors that complements Lantheus' PNT2003 therapeutic candidate. The acquisition also expands Lantheus' oncology pipeline with multiple clinical and pre-clinical theranostic pairs.
The transaction is expected to close in the second half of 2025, subject to customary conditions and regulatory clearances. Lantheus has reaffirmed its FY 2024 guidance with revenue of $1.51-1.52 billion and adjusted fully diluted EPS of $6.65-6.70.
Lantheus Holdings (NASDAQ: LNTH) has announced a definitive agreement to acquire Evergreen Theragnostics for an upfront payment of $250 million, with potential additional milestone payments of up to $752.5 million. The acquisition aims to transform Lantheus into a fully integrated radiopharmaceutical company.
The deal brings significant strategic advantages, including Evergreen's scalable manufacturing infrastructure, CDMO services, and OCTEVY™, a registrational-stage diagnostic agent for neuroendocrine tumors that complements Lantheus' therapeutic candidate PNT2003. The acquisition also expands Lantheus' oncology pipeline with multiple clinical and pre-clinical theranostic pairs.
The transaction is expected to close in the second half of 2025, subject to customary conditions. Lantheus has reaffirmed its FY 2024 guidance with revenue of $1.51-1.52 billion and adjusted fully diluted EPS of $6.65-6.70.
Lantheus Holdings (NASDAQ: LNTH) has announced a $250 million share repurchase program to be executed over the next twelve months. The company plans to begin repurchases in Q4 2023 through open market transactions, private negotiations, and other legal means, with timing and amounts determined by management based on market conditions. The program demonstrates the board's confidence in Lantheus' leadership in radiopharmaceuticals and growth potential. The company aims to balance capital return to shareholders while pursuing business development opportunities to expand its radiopharmaceutical portfolio.
Lantheus Holdings (NASDAQ: LNTH), a leading radiopharmaceutical company, has announced its participation in the upcoming Jefferies London Healthcare Conference. Bob Marshall, Chief Financial Officer and Treasurer, will deliver a presentation on Wednesday, November 20, at 1:00 p.m. GMT (8 a.m. EST). The presentation will be accessible via live webcast through the Investors section of Lantheus's website. A replay will remain available for at least 30 days after the live event.
Lantheus Holdings (NASDAQ: LNTH) responds to CMS' updated payment rates for Calendar Year 2025 Medicare Hospital Outpatient Prospective Payment System. The new rules will 'unbundle' diagnostic radiopharmaceuticals, enabling separate payments for those costing over $630 per day. This change affects approximately 20% of traditional Medicare Fee for Service patients in hospital outpatient settings. PYLARIFY®, the company's PSMA PET imaging agent, is expected to exceed $1 billion in sales in 2024 and maintain its position as the #1 ordered PSMA PET imaging agent in the U.S. The new payment system will be effective January 1, 2025.
Lantheus (LNTH) reported strong Q3 2024 results with worldwide revenue of $378.7 million, up 18.4% year-over-year. PYLARIFY sales reached $259.8 million (+20.6%) and is on track to exceed $1 billion in 2024. DEFINITY sales grew 14.3% to $77.0 million. The company reported GAAP EPS of $1.79 and adjusted EPS of $1.70. Cash position strengthened to $866.4 million. The company narrowed its FY2024 guidance towards the higher end, projecting revenue of $1.51-1.52 billion and adjusted EPS of $6.65-6.70.
FAQ
What is the current stock price of Lantheus Holding (LNTH)?
What is the market cap of Lantheus Holding (LNTH)?
What does Lantheus Holdings, Inc. specialize in?
What are some key products of Lantheus?
Where is Lantheus Holdings headquartered?
What are the core business units of Lantheus?
Who is the current CEO of Lantheus Holdings?
What recent achievements has Lantheus accomplished?
What financial growth did Lantheus achieve in 2023?
What is the significance of DEFINITY® Vial?
What types of diseases does Lantheus focus on in their diagnostics?
How does Lantheus contribute to precision medicine?
